- Home
- SGHT vs SPXX Comparison
SGHT vs SPXX Comparison
Compare SGHT & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- SPXX
- Stock Information
- Founded
- SGHT 2011
- SPXX 2004
- Country
- SGHT United States
- SPXX United States
- Employees
- SGHT N/A
- SPXX N/A
- Industry
- SGHT Medical Specialities
- SPXX Trusts Except Educational Religious and Charitable
- Sector
- SGHT Health Care
- SPXX Finance
- Exchange
- SGHT Nasdaq
- SPXX Nasdaq
- Market Cap
- SGHT 304.4M
- SPXX 302.8M
- IPO Year
- SGHT 2021
- SPXX N/A
- Fundamental
- Price
- SGHT $3.61
- SPXX $17.76
- Analyst Decision
- SGHT Buy
- SPXX
- Analyst Count
- SGHT 7
- SPXX 0
- Target Price
- SGHT $6.27
- SPXX N/A
- AVG Volume (30 Days)
- SGHT 206.9K
- SPXX 51.3K
- Earning Date
- SGHT 11-07-2024
- SPXX 01-01-0001
- Dividend Yield
- SGHT N/A
- SPXX 7.55%
- EPS Growth
- SGHT N/A
- SPXX N/A
- EPS
- SGHT N/A
- SPXX N/A
- Revenue
- SGHT $79,543,000.00
- SPXX N/A
- Revenue This Year
- SGHT $2.13
- SPXX N/A
- Revenue Next Year
- SGHT $7.99
- SPXX N/A
- P/E Ratio
- SGHT N/A
- SPXX N/A
- Revenue Growth
- SGHT N/A
- SPXX N/A
- 52 Week Low
- SGHT $3.30
- SPXX $13.57
- 52 Week High
- SGHT $8.45
- SPXX $16.05
- Technical
- Relative Strength Index (RSI)
- SGHT 41.47
- SPXX 60.45
- Support Level
- SGHT $3.45
- SPXX $16.89
- Resistance Level
- SGHT $3.64
- SPXX $18.00
- Average True Range (ATR)
- SGHT 0.19
- SPXX 0.21
- MACD
- SGHT 0.03
- SPXX -0.03
- Stochastic Oscillator
- SGHT 38.04
- SPXX 77.93
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio (with a 55% long-term target) in an effort to enhance the Fund's risk-adjusted returns.